SCHEMBL1002037

SCHEMBL1002037

Oc1[c]oc2ccccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.36
CA9 Q16790 3/20 0.36
CA1 P00915 2/20 0.36
IDO1 P14902 1/20 0.36
MAOA P21397 5/20 0.34
KDM4E B2RXH2 4/20 0.34
CYP3A4 P08684 3/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34
PGAM1 P18669 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
LMNA P02545 2/20 0.33
TP53 P04637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18575031 0.71 MAOA (0.34) MAOAKDM4ECYP3A4ALDH1A1MAPT
SCHEMBL221025 0.71 CYP1A2 (0.36) MAOAKDM4ECYP3A4ALDH1A1MAPT
SCHEMBL8304401 0.71 KDM4E (0.38) CA1MAOAKDM4ECYP3A4ALDH1A1
SCHEMBL3235744 0.71 AHR (0.38) MAOAKDM4ECYP3A4ALDH1A1MAPT
SCHEMBL546688 0.71 MAOA (0.34) MAOAKDM4ECYP3A4ALDH1A1MAPT
SCHEMBL11728712 0.71 AKR1C3 (0.42) CA12CA9CA1IDO1MAOA
SCHEMBL20562769 0.70 KDM4E (0.41) CA12CA9CA1MAOAKDM4E
SCHEMBL638083 0.69 CA12 (0.41) CA12CA9KDM4EALDH1A1MAPT
SCHEMBL6863801 0.69 ALDH1A1 (0.39) MAOAKDM4ECYP3A4ALDH1A1MAPT
SCHEMBL2958656 0.68 CA1 (0.36) CA12CA9CA1MAOAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110713588-B Hardmask composition, hardmask layer and method of forming pattern 三星SDI株式会社 2022-08-09 CN claimed
US-11214678-B2 Hardmask composition, hardmask layer and method of forming patterns SAMSUNG SDI CO., LTD. (KR) 2022-01-04 US claimed
CN-110713588-A Hardmask composition, hardmask layer and method of forming pattern 三星SDI株式会社 2020-01-21 CN claimed
US-6794383-B2 Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-09-21 US claimed
US-11918568-B2 Fused ring compound having urea structure Sanford Burnham Prebys Medical Discovery Institute (US) 2024-03-05 US disclosed
CN-115252732-B Traditional Chinese medicine composition for clearing lung and relieving cough and application thereof 宁波市第一医院 2023-11-14 CN disclosed
CN-111378084-B Polymer and hardmask composition and method of forming pattern 三星SDI株式会社 2023-08-08 CN disclosed
EP-3818053-B1 FUSED RING COMPOUND HAVING UREA STRUCTURE SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) 2023-03-29 EP disclosed
CN-115252732-A Traditional Chinese medicine composition for clearing lung and relieving cough and application thereof 宁波市第一医院 2022-11-01 CN disclosed
CN-110713588-B Hardmask composition, hardmask layer and method of forming pattern 三星SDI株式会社 2022-08-09 CN disclosed
US-11214678-B2 Hardmask composition, hardmask layer and method of forming patterns SAMSUNG SDI CO., LTD. (KR) 2022-01-04 US disclosed
US-20210361636-A1 FUSED RING COMPOUND HAVING UREA STRUCTURE DAIICHI SANKYO COMPANY LIMITED (JP) 2021-11-25 US disclosed
EP-0324610-B1 Thieno[2,3-d]azepine derivatives, process for their preparation and pharmaceutical compositions containing them LILLY INDUSTRIES LTD (GB) 1994-04-13 EP disclosed
US-5028602-A Thieno-(3,4-d)azepines, central nervous system disorders LILLY INDUSTRIES LIMITED (GB) 1991-07-02 US disclosed
EP-0398504-A1 Thieno[3,4-d]azepine derivatives, process for their preparation and pharmaceutical compositions containing them LILLY INDUSTRIES LIMITED (GB) 1990-11-22 EP disclosed
US-4904653-A Thieno[2,3-O]azepine compounds and CNS affecting use thereof LILLY INDUSTRIES LIMITED (GB) 1990-02-27 US disclosed
EP-0324610-A2 Thieno[2,3-d]azepine derivatives, process for their preparation and pharmaceutical compositions containing them LILLY INDUSTRIES LIMITED (GB) 1989-07-19 EP disclosed
US-4751222-A 2,3,4,5-tetrahydro-1H-3-benzazepines and CNS affecting use thereof NOVO INDUSTRI A/S (DK) 1988-06-14 US disclosed
EP-0200455-A2 2,3,4,5-tetrahydro-1H-3-benzazepines substituted in position 5 NOVO NORDISK A/S (DK) 1986-11-05 EP disclosed
US-4185110-A ANTIALLERGENS CIBA-GEIGY CORPORATION (US) 1980-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210361636-A1 FUSED RING COMPOUND HAVING UREA STRUCTURE NAMPT, NME4, ABAT CA12 4717/4885CA9 4186/4885CA1 4742/4885
US-11918568-B2 Fused ring compound having urea structure NAMPT, NME4, ABAT CA12 4717/4885CA9 4186/4885CA1 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.